Business Wire

Micreos Pharmaceuticals Welcomes Trine Ahlgreen and Carsten Edwards to Its Executive Team to Accelerate Its Next Phase of Development

Share

Micreos Pharmaceuticals today announces the expansion of its leadership team to include Trine Ahlgreen as Chief Business Officer and Carsten Edwards as Chief Development Officer. Their significant leadership experience within large, global pharmaceutical organisations will enable Micreos to accelerate the journey of developing viable alternatives to traditional antibiotics in select medical indications by leveraging proprietary endolysin technology, which selectively targets and kills harmful bacteria while preserving the rest of the microbiome.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220405005632/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Micreos Pharmaceuticals welcomes Trine Ahlgreen and Carsten Edwards to its executive team. (Photo: Business Wire)

The addition of Trine Ahlgreen and Carsten Edwards to the senior team represents an important step forward in building the strategic capabilities to make the right choices in the months and years ahead.

As Chief Business Officer, Trine Ahlgreen is responsible for building-out the pharmaceutical business strategy including commercial input into the development program and the selection & prioritisation of new indications where bacteria are the underlying pathogen. She will also be responsible for forging partnerships with pharma and diagnostic companies to design the go-to-market strategies and deliver solutions to improve patient standards-of-care. Trine has spent the last 20 years at Novo Nordisk in various geographies leading marketing and sales operations across the company’s portfolio.

Carsten Edwards brings 30 years of diverse experience in value, access, pricing, and health economics outcomes functions across companies including Novo Nordisk, AbbVie, and Bristol-Myers Squibb. Carsten has also worked in consultancy and is a recognised expert in drug development and the data packages required to secure global patient access. As Chief Development Officer, Carsten will lead Micreos Pharmaceuticals’ entire drug development programs, including pre-clinical, analytical methods development, API manufacturing, and drug formulation development, to optimise therapeutic effect and to maximise patient outcomes

“We are delighted to expand our senior team at this critical moment in the Micreos

Pharmaceuticals’ journey and to attract people of the calibre of Carsten and Trine into our organisation. They are among the very best people in our industry,” said Matt Regan, CEO of Micreos Pharmaceuticals, who joined the company in October 2021. “Trine and Carsten bring significant pharmaceutical industry experience, success, and know-how that will help us to make the right choices in early drug discovery and in our pharmaceutical development programs to ensure that we are raising the standards of care for patients in our selected disease areas.”

About Micreos Pharmaceuticals

Micreos Pharmaceuticals develops new biological therapies based on the targeted killing of unwanted bacteria, which has medical potential in a broad range of applications. The company is viewed as a global leader in this field. Its proprietary endolysin technology has been created together with the Swiss Federal Technology Institute, ETH in Zurich.

Micreos Pharmaceuticals is located in Zug, Switzerland and has a Drug discovery / Technology research centre in Zurich, Switzerland with a Drug development & Clinical operation in Bilthoven in the Netherlands.

About Antimicrobial Resistance (AMR)

AMR is an issue of growing global importance which results in 750,000 deaths per year. It occurs when pathogens adapt so that the drugs used to treat infections become less effective. If not addressed, the spread of antibiotic-resistant pathogens could continue to rise, leading to highly dangerous superbugs. The number of annual global deaths from AMR is projected to increase to 10 million by 2050 — which is more people than die globally of cancer today – unless successful alternatives to antibiotics are developed.

Micreos Pharmaceuticals intends to play a very significant role in addressing AMR and the great unmet medical need for a safe alternative to antibiotics.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Melanie Stinn, Head of Corporate Communications
m.stinn@micreos.com
+49-151-2126-1437

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting27.5.2022 16:00:00 EEST | Press release

LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract Number:e16102 Abstract Title: Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis. The abstract is about the cohort A, stage I of the ongoing global phase Ⅲ trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis (clinicaltrials.gov: NCT04222114). Worldwide, GC is one of the most common cancers, contributing to more than 1 million cases per year and 5.6% of all cancer diagnoses [1]. Approximately 50% of the advanced GC patients will develop

FEELM unveils the world's first ceramic coil disposable pod solution at Vaper Expo UK 202227.5.2022 14:38:00 EEST | Press release

FEELM, the flagship atomization tech brand belonging to SMOORE, today showcased the world's first ceramic coil disposable pod solution series, FEELM Max at Vaper Expo UK 2022 in Birmingham, UK. By launching the solution and showcasing its cutting-edge ceramic coil heating technology, FEELM is introducing ceramic coil to the emerging category of disposable vape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220527005197/en/ (Photo: Business Wire) As a new category in the ascendant, the disposable vape has been growing in popularity since 2020. The market size of disposable (closed system) vaping product has grown to approximately USD2.125 billion in 2021, accounting for 22.7% of global vaping device market share; and it is expected to increase at a GAGR of over 28% from 2022 to 2026, being the fastest-growing category among all vaping products, according to the estimates of Frost & Suvillian. In 2022, the market size of disp

TYAN Brings Modern HPC Server Platforms for Data Centers at ISC 202227.5.2022 10:00:00 EEST | Press release

TYAN®, an industry-leading server platform design manufacturer and MiTAC Computing Technology Corporation subsidiary, will exhibit its latest HPC platforms powered by 3rd Gen AMD EPYC™ Processors with AMD 3D V-Cache™ technology for data centers deployments at the ISC 2022 event from May 30th to June 1st at booth #D400. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220527005002/en/ TYAN’s Server Platforms Powered by AMD EPYC 7003 Series Processors Provide the Best Foundation for Data Centers that Can be Tailored to Specific Workloads (Photo: Business Wire) “The amount of data generated by humans and machines has increased exponentially and this requires a steady increase of data center compute performance, therefore, modern data centers need balanced hardware to efficiently manage growing data volumes,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's Server Infrastructure Business Unit. “TYAN’s ser

Mavenir’s Containerized Open vRAN Small Cell Solution Wins Award for Outstanding Contribution to Emerging Technology or Architecture27.5.2022 10:00:00 EEST | Press release

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced to have won the SCF Small Cell Awards 2022 for Outstanding Contribution to Emerging Technology or Architecture, for its design and delivery of the first fully containerized small cell Open Virtualized Radio Access Network (Open vRAN), for indoor and outdoor connectivity. Mavenir’s containerized Open vRAN solution is a first of its kind and combines the interoperability of Open RAN with the portability and flexibility of containers. This small cell solution brings the same future-forward approaches of Open RAN and containerization having significant impacts in macro networks to small cell networks. The deployment of a containerized solution is a significant milestone in the evolution of connectivity, moving away from the physical infrastructure to a digital cloud-based environment. Containers take virtualizati

Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma27.5.2022 00:25:00 EEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom